

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER: **10/608,354**
FILING DATE: **6/27/2003**
FIRST NAMED INVENTOR: **Stanley Crooke**
ART UNIT: **1634**
EXAMINER NAME: **Frank Wei Min Lu**
CONFIRMATION NUMBER: **2899**
ATTORNEY DOCKET NUMBER: **MSIBIS-0002USC2**
TITLE: **MASS SPECTROMETRIC METHODS
FOR BIOMOLECULAR SCREENING**

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
Under 37 C.F.R. §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 C.F.R. §§ 1.56 and 1.97-98, enclosed herewith is PTO Forms PTO/SB/08A and PTO/SB/08B listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed after three months of the filing date of this national application and after the mailing date of the first official action on the merits but before the mailing date of a final office action, a notice of allowance, or

an office action closing prosecution. Applicants, therefore, submit herewith the fee set forth under 37 C.F.R. § 1.17(p) for submission of this Information Disclosure Statement under 37 C.F.R. § 1.97(c).

Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.

Respectfully submitted,


Jason Perrone, J.D.
Registration No.: **52,887**
Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad, CA 92008

Dated: Oct. 1, 2008